Drugs / Cemsidomide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07280013 | Feb 2026 → Dec 2028 expected | plasma cell myeloma | C4 Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04756726 | Apr 2021 → Sep 2026 overdue | non-Hodgkin lymphoma, plasma cell myeloma | C4 Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07284758 | Feb 2026 → Mar 2030 expected | plasma cell myeloma | C4 Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
All press releases naming this drug 6 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cemsidomide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04756726 ↗ |
| Known as | Cemsidomida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095227 ↗ |
| Known as | CFT7455 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095227 ↗ |
| Modality | Small molecule | — CHEMBL5095227 ↗ |
| Route | Oral | “oral cemsidomide” NCT04756726 ↗ |
| Target | IKZF1 | “IKZF1/3 degrader” NCT07280013 ↗ |